Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of encorafenib + binimetinib + pembrolizumab versus placebo + pembrolizumab in BRAF V600E/K-mutant advanced melanoma
MOH_2022-11-07_012165Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of encorafenib, binimetinib and pembrolizumab in melanoma (2 arms), sponsored by Pfizer. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2022-11-07_012165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-07_012165.